Editas Medicine Inc Quick Ratio (EDIT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Editas Medicine Inc   (NASDAQ: EDIT)

Editas Medicine Inc 's Quick Ratio

EDIT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 3.09 below Editas Medicine Inc average.

Within Biotechnology & Pharmaceuticals industry 77 other companies have achieved higher Quick Ratio than Editas Medicine Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 166 to 1095.

Explain Quick Ratio?
How much Cash & cash equivalents EDIT´s has?
What are EDIT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EDIT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 3.79 % -45.59 % -40.12 % -14.62 % -11.26 %
Y / Y Cash & cash equivalent Change 18.57 % -44.04 % -45.67 % -37.51 % -36.05 %
Quick Ratio MRQ 3.09 3.11 3.17 2.68 2.71
EDIT's Total Ranking # 1095 # 166 # 639 # 0 # 739
Seq. Current Liabilities Change 72.04 % -13.98 % -25.14 % -6.32 % -9.82 %
Seq. Cash & cash equivalent Change 71.17 % -15.68 % -11.47 % -7.2 % -19.22 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 78
Healthcare Sector # 399
Overall Market # 1095


Quick Ratio Statistics
High Average Low
22.56 8.67 2.68
(Mar 31 2016)   (Sep 30 2025)




Financial Statements
Editas Medicine Inc 's Current Liabilities $ 68 Millions Visit EDIT's Balance sheet
Editas Medicine Inc 's Cash & cash equivalent $ 212 Millions Visit EDIT's Balance sheet
Source of EDIT's Sales Visit EDIT's Sales by Geography


Cumulative Editas Medicine Inc 's Quick Ratio

EDIT's Quick Ratio for the trailling 12 Months

EDIT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -25.08 % -28.03 % -14.91 % 0.61 % 9.91 %
Y / Y Cash & cash equivalent TTM Growth -30.7 % -40.64 % -35.89 % -28.23 % -25.12 %
Quick Ratio TTM 2.99 2.87 2.88 3 3.24
Total Ranking TTM # 3736 # 952 # 2428 # 0 # 2691
Seq. Current Liabilities TTM Growth 1.17 % -13.49 % -11.14 % -3.67 % -2.82 %
Seq. Cash & cash equivalent TTM Growth 5.39 % -13.67 % -14.76 % -10.64 % -9.72 %

Quick ratio ranking by company, industry and sector >> Back to EDIT Financial Strength Comparisons >> Go to Compare EDIT Quick Ratio to its Competitors

On the trailing twelve months basis EDIT Cash & cash equivalent increased by 18.57 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Editas Medicine Inc 's Quick Ratio to 2.99, Quick Ratio remained below EDIT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Editas Medicine Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 952 to 3736.

Explain Quick Ratio?
How much Cash & cash equivalents EDIT´s has?
What are EDIT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 873
Within the Market # 3736


trailing twelve months Quick Ratio Statistics
High Average Low
11.78 3.94 1.24
(Dec 31 2016)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions
Redwoods Acquisition Corp  7.69 $ 9.300  Millions$ 1.210  Millions
Cardiff Oncology Inc   7.04 $ 76.005  Millions$ 10.797  Millions
Black Diamond Therapeutics Inc   6.98 $ 110.506  Millions$ 15.843  Millions
Immunovant Inc   6.81 $ 797.798  Millions$ 117.102  Millions
Scholar Rock Holding Corp  6.81 $ 492.088  Millions$ 72.242  Millions
Fennec Pharmaceuticals Inc   6.66 $ 82.498  Millions$ 12.394  Millions
Krystal Biotech Inc   6.64 $ 845.600  Millions$ 127.397  Millions
Caribou Biosciences Inc   6.33 $ 113.800  Millions$ 17.974  Millions
Cognition Therapeutics inc   6.24 $ 34.012  Millions$ 5.450  Millions
C4 Therapeutics Inc   6.24 $ 300.854  Millions$ 48.247  Millions
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions
Revolution Medicines Inc   5.54 $ 3,937.969  Millions$ 710.589  Millions
Humacyte Inc   5.35 $ 79.903  Millions$ 14.948  Millions
Invivyd Inc   5.16 $ 160.080  Millions$ 31.028  Millions
Lineage Cell Therapeutics Inc   5.13 $ 50.855  Millions$ 9.914  Millions
Alector Inc   5.05 $ 172.798  Millions$ 34.236  Millions
Atyr Pharma Inc   5.04 $ 57.418  Millions$ 11.396  Millions
Vericel Corporation  5.04 $ 264.531  Millions$ 52.532  Millions
Inhibrx Biosciences Inc   4.75 $ 133.344  Millions$ 28.064  Millions
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions
Recursion Pharmaceuticals Inc   4.55 $ 545.683  Millions$ 119.886  Millions
Prime Medicine Inc   4.50 $ 142.720  Millions$ 31.692  Millions
Immunitybio inc   4.50 $ 357.371  Millions$ 79.392  Millions

Date modified: 2026-09-08T17:29:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.